Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pembrolizumab · 1 trial · 1 indication
Patients achieving (\>30%) reduction in ultrasound estimate of breast mass volume (mL) at the end of 2 cycles investigational therapy
| Arm | Type | Description |
|---|---|---|
| Pembrolizumab + INBRX-106 | EXPERIMENTAL | Patients will be given pembrolizumab at a dose of 200mg IV in combination with INBRX-106 at a dose of 0.1mg/kg IV every 3 weeks. |
| Name | Type | Description |
|---|---|---|
| Pembrolizumab | DRUG | Drug will be delivered per standard-of-care as established by trial Keynote-522. |
| INBRX-106 | DRUG | INBRX-106 is a hexavalent, recombinant humanized IgG1, OX40 agonist antibody that targets the human OX40 receptor (TNFRSF4, UniProtKB: P43489). INBRX-106 is based on a sdAb platform and, in detail, 3 identical humanized camelid heavy chain-only antibody binding domains (VHHs) targeting OX40 are joined end-to-end and with an Fc based on human IgG1 to create a molecule that homo-dimerizes into an antibody targeting a total of 6 OX40 receptors. |
Inclusion Criteria: 1. Age ≥ 18 years, inclusive of all genders. 2. Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 2. 3. Patients must have histologically confirmed TNBC (ER/PR ≤ 10% allowed, HER2- as defined by ASCO guidelines). HER2 negative permitted to enroll ...
Pembrolizumab is being studied in combination with INBRX-106 as a neoadjuvant treatment for patients with Stage II/III Triple Negative Breast Cancer (TNBC). The therapy is administered before surgery to assess its effect on the tumor. This is an investigational use, and pembrolizumab is not approved for this specific indication.
Pembrolizumab targets PDCD1, which encodes the programmed cell death protein 1 (PD-1) receptor. As an inhibitor of PDCD1, it blocks the PD-1 pathway, which can help the immune system recognize and attack cancer cells. This mechanism is relevant to its use in oncology, including the ongoing trial in Triple Negative Breast Cancer.
Pembrolizumab is being developed by Inhibrx Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol INBX. The company is conducting a Phase 2 clinical trial evaluating pembrolizumab in combination with INBRX-106 for the treatment of Triple Negative Breast Cancer.
Pembrolizumab is in Phase 2 clinical development for Triple Negative Breast Cancer. The ongoing trial, NCT06353997, is currently recruiting participants in the United States. Pembrolizumab is an investigational agent for this indication and has not yet received FDA approval for this use.
Pembrolizumab is being evaluated in a single Phase 2 clinical trial with the identifier NCT06353997. The trial is titled "Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients" and is currently recruiting. The study is enrolling 12 participants aged 18 years and older in the United States.
Yes, pembrolizumab 200 mg refers to the same drug, pembrolizumab. The 200 mg designation indicates the specific dose being studied in the clinical trial. In the context of this trial, pembrolizumab is administered at a 200 mg dose in combination with INBRX-106 for the treatment of Triple Negative Breast Cancer.